Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 1251 to 1300 of 1380 results for patients and public

  1. Sacubitril valsartan for treating chronic heart failure with preserved ejection fraction [ID1606]

    Discontinued [GID-TA11257]

    Technology appraisal guidance
    Discontinued

  2. Liposomal vincristine for treating Philadelphia chromosome-negative acute lymphoblastic leukaemia after two therapies [ID954]

    Discontinued [GID-TA11181]

    Technology appraisal guidance
    Discontinued

  3. Tislelizumab in combination for untreated advanced non-small-cell lung cancer [ID6162]

    In development [GID-TA11101] Expected publication date: TBC

    Technology appraisal guidance
    In development

  4. Bimekizumab for treating ankylosing spondylitis ID4011

    Discontinued [GID-TA11171]

    Technology appraisal guidance
    Discontinued

  5. Tislelizumab for treating advanced non-small-cell lung cancer after platinum-based chemotherapy [ID6161]

    In development [GID-TA11099] Expected publication date: TBC

    Technology appraisal guidance
    In development

  6. Alzheimer's disease (early) - gantenerumab [ID6142]

    In development [GID-TA11269] Expected publication date: TBC

    Technology appraisal guidance
    In development

  7. Dupilumab for treating chronic spontaneous urticaria in people 12 years and over [ID4055]

    In development [GID-TA11272] Expected publication date: TBC

    Technology appraisal guidance
    In development

  8. Venetoclax with bortezomib and dexamethasone for treating relapsed or refractory multiple myeloma ID1565

    In development [GID-TA10502] Expected publication date: TBC

    Technology appraisal guidance
    In development

  9. Telisotuzumab vedotin for treating c-MET overexpressed, EGFR wild-type, non-squamous advanced non-small-cell lung cancer after 1 or more systemic treatments [ID6253]

    In development [GID-TA11274] Expected publication date: TBC

    Technology appraisal guidance
    In development

  10. Zio XT for detecting cardiac arrhythmias

    In development [GID-MT591] Expected publication date: TBC

    Medical technologies guidance
    In development

  11. Triptorelin for the adjuvant treatment of early breast cancer in premenopausal women [ID976]

    Discontinued [GID-TA11261]

    Technology appraisal guidance
    Discontinued

  12. Ataluren for treating cystic fibrosis in people with a CFTR gene nonsense mutation [ID955]

    Discontinued [GID-TA11262]

    Technology appraisal guidance
    Discontinued

  13. Rolofylline for the treatment of acute heart failure [ID96]

    Discontinued [GID-TA11258]

    Technology appraisal guidance
    Discontinued

  14. Capecitabine for the treatment of advanced pancreatic cancer [ID127]

    Discontinued [GID-TA11239]

    Technology appraisal guidance
    Discontinued

  15. Pazopanib for adjuvant treatment of locally advanced renal cell carcinoma [ID1091]

    Discontinued [GID-TA11240]

    Technology appraisal guidance
    Discontinued

  16. Canakinumab and tocilizumab for treating systemic juvenile idiopathic arthritis [ID983]

    Discontinued [GID-TA11241]

    Technology appraisal guidance
    Discontinued

  17. Otilimab for treating moderate to severe rheumatoid arthritis [ID6171]

    In development [GID-TA11108] Expected publication date: TBC

    Technology appraisal guidance
    In development

  18. Atezolizumab (Tecentriq) + bevacizumab (Avastin) + chemotherapy for ovarian cancer TS ID 10701

    In development [GID-TA11157] Expected publication date: TBC

    Technology appraisal guidance
    In development

  19. Tislelizumab for previously treated advanced oesophageal squamous cell cancer [ID4070]

    In development [GID-TA11042] Expected publication date: TBC

    Technology appraisal guidance
    In development

  20. ALXN1840 for treating Wilson disease TS ID 9950

    In development [GID-TA11449] Expected publication date: TBC

    Technology appraisal guidance
    In development

  21. Bimekizumab for treating active non-radiographic axial spondyloarthritis [ID4010]

    Discontinued [GID-TA11151]

    Technology appraisal guidance
    Discontinued

  22. Letermovir for preventing cytomegalovirus infection after a kidney transplant [ID6166]

    In development [GID-TA11107] Expected publication date: TBC

    Technology appraisal guidance
    In development

  23. Terevalefim for treating delayed graft function after kidney transplant [ID1490]

    Discontinued [GID-TA11098]

    Technology appraisal guidance
    Discontinued

  24. Abemaciclib with abiraterone acetate and prednisone for treating hormone-relapsed metastatic prostate cancer [ID6230]

    In development [GID-TA11252] Expected publication date: TBC

    Technology appraisal guidance
    In development

  25. Nivolumab with chemotherapy for untreated unresectable or metastatic urothelial cancer [ID5102]

    In development [GID-TA11010] Expected publication date: TBC

    Technology appraisal guidance
    In development

  26. Gilteritinib for maintenance treatment of FLT3-mutation-positive acute myeloid leukaemia after stem cell transplant [ID6243]

    In development [GID-TA11255] Expected publication date: TBC

    Technology appraisal guidance
    In development

  27. Olaparib with cediranib for treating platinum-resistant recurrent ovarian cancer after 1 or 2 therapies [ID4065]

    In development [GID-TA11033] Expected publication date: TBC

    Technology appraisal guidance
    In development

  28. Vandetanib for treating metastatic, differentiated thyroid cancer refractory to or unsuitable for radioiodine therapy [ID907]

    Discontinued [GID-TA11259]

    Technology appraisal guidance
    Discontinued

  29. Bavituximab for treating non-squamous non-small-cell lung cancer after platinum-based chemotherapy [ID975]

    Discontinued [GID-TA11260]

    Technology appraisal guidance
    Discontinued

  30. Olaparib for maintenance treatment of BRCA-negative platinum-sensitive relapsed ovarian, fallopian tube or primary peritoneal cancer [ID6205]

    In development [GID-TA10965] Expected publication date: TBC

    Technology appraisal guidance
    In development

  31. Lymphoma (diffuse large B-cell, untreated) – liposomal vincristine [ID1123]

    Discontinued [GID-TA11208]

    Technology appraisal guidance
    Discontinued

  32. Masitinib for treating relapsed or refractory peripheral T-cell non-Hodgkin lymphoma [ID1125]

    Discontinued [GID-TA11173]

    Technology appraisal guidance
    Discontinued

  33. Nivolumab for adjuvant treatment of localised renal cell carcinoma [ID6362]

    In development [GID-TA11421] Expected publication date: TBC

    Technology appraisal guidance
    In development

  34. Tusamitamab ravtansine for previously treated CEACAM5-positive metastatic non-squamous non-small-cell lung cancer [ID4061]

    In development [GID-TA11034] Expected publication date: TBC

    Technology appraisal guidance
    In development

  35. Amyotrophic lateral sclerosis - SAR443820 [ID6386]

    In development [GID-TA11476] Expected publication date: TBC

    Technology appraisal guidance
    In development

  36. Evobrutinib for treating relapsing multiple sclerosis [ID6313]

    In development [GID-TA11357] Expected publication date: TBC

    Technology appraisal guidance
    In development

  37. Durvalumab with chemoradiation for untreated locally advanced cervical cancer [ID5081]

    Discontinued [GID-TA10963]

    Technology appraisal guidance
    Discontinued

  38. Subcutaneous atezolizumab for treating locally advanced or metastatic non-small-cell lung cancer after platinum-based chemotherapy TS ID 11801

    Discontinued [GID-TA11180]

    Technology appraisal guidance
    Discontinued

  39. Maribavir for cytomegalovirus infection after haematopoietic stem cell transplant [ID5075]

    In development [GID-TA10958] Expected publication date: TBC

    Technology appraisal guidance
    In development

  40. Nivolumab with ipilimumab for untreated unresectable stage 3 non-small-cell lung cancer [ID6248]

    In development [GID-TA11253] Expected publication date: TBC

    Technology appraisal guidance
    In development

  41. Canakinumab for adjuvant treatment of resectable or resected stage 2A to 3B non-small-cell lung cancer [ID5114]

    In development [GID-TA11026] Expected publication date: TBC

    Technology appraisal guidance
    In development

  42. Belantamab mafodotin for treating relapsed or refractory multiple myeloma after 2 therapies [ID5108]

    In development [GID-TA11018] Expected publication date: TBC

    Technology appraisal guidance
    In development

  43. Pembrolizumab with lenvatinib for previously treated metastatic colorectal cancer [ID5112]

    In development [GID-TA11020] Expected publication date: TBC

    Technology appraisal guidance
    In development

  44. Pemigatinib for treating myeloid or lymphoid neoplasms with a FGFR1 rearrangement [ID6172]

    In development [GID-TA11109] Expected publication date: TBC

    Technology appraisal guidance
    In development

  45. Empagliflozin for preventing cardiovascular events after acute myocardial infarction [ID6240]

    In development [GID-TA11265] Expected publication date: TBC

    Technology appraisal guidance
    In development

  46. Oral paclitaxel with encequidar for treating advanced breast cancer [ID5111]

    In development [GID-TA11022] Expected publication date: TBC

    Technology appraisal guidance
    In development

  47. Benralizumab for treating eosinophilic oesophagitis in people aged 12 to 65 [ID5093]

    In development [GID-TA10995] Expected publication date: TBC

    Technology appraisal guidance
    In development

  48. Atezolizumab for adjuvant treatment of renal cell carcinoma with a high risk of metastasis [ID5101]

    In development [GID-TA11000] Expected publication date: TBC

    Technology appraisal guidance
    In development

  49. Atezolizumab with cabozantinib for treating metastatic non-small-cell lung cancer after platinum-based chemotherapy and 1 PD-L1 checkpoint inhibitor [ID6213]

    In development [GID-TA11204] Expected publication date: TBC

    Technology appraisal guidance
    In development

  50. Nivolumab for adjuvant treatment of completely resected melanoma at high risk of recurrence in people aged 12 and over [ID6189]

    In development [GID-TA11138] Expected publication date: TBC

    Technology appraisal guidance
    In development